Approved by the FDA, EMA, and other regulatory agencies, upadacitinib (Rinvoq) treats chronic inflammatory diseases such as RA, psoriatic arthritis, and ulcerative colitis by inhibiting JAK1, disrupting cytokine signaling. This evidence concerns the gene JAK1 and psoriatic arthritis.